TARA

Protara Therapeutics Inc

2.44

Oct 22 • 3:59 PM ET -0.06 (-2.40%)

2.37

Aftermarket • 6:06 PM ET -0.07 (-2.87%)

Healthcare Biotechnology USA Micro NASD

Peers: ENGN CGON IBRX URGN CADL JNJ PGEN CHRS TLX IRWD

| Held by: VTI IWM VXF IWN VTWO DFAS IWC AVSC SBIO BUSM

Scroll to Statements

Index	RUT
Market Cap	144.19M
Enterprise Value	4.45M
Income	-70.02M
Sales	0.00M
Book/sh	2.73
Cash/sh	2.41
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	51
IPO	Oct 22, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.89
P/C	1.01
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	10.97
Current Ratio	10.97
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-1.35
EPS next Y	-1.63
EPS next Q	-0.37
EPS this Y	-3.52%
EPS next Y	-17.82%
EPS next 5Y	23.07%
EPS past 3/5Y	38.83% 22.18%
Sales past 3/5Y	- -
EPS Y/Y TTM	17.06%
Sales Y/Y TTM	-
EPS Q/Q	-0.37%
Sales Q/Q	-
Earnings	Aug 11 BMO
EPS/Sales Surpr.	-10.53% -

Insider Own	11.68%
Insider Trans	-3.03%
Inst Own	69.24%
Inst Trans	4.39%
ROA	-42.05%
ROE	-45.80%
ROIC	-43.01%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-9.38%
SMA50	-27.61%
SMA200	-47.55%
Trades

Shs Outstand	59.08M
Shs Float	52.19M
Short Float	11.10%
Short Ratio	6.49
Short Interest	5.79M
52W High	7.82 -68.80%
52W Low	2.30 6.32%
Volatility	6.36% 7.14%
ATR (14)	0.18
RSI (14)	32.02
Beta	1.51
Rel Volume	1.97
Avg Volume	892.77K
Volume	1,761,428

Perf Week	1.67%
Perf Month	-31.07%
Perf Quarter	-39.30%
Perf Half Y	-53.61%
Perf YTD	-54.22%
Perf Year	-52.99%
Perf 3Y	72.44%
Perf 5Y	-63.64%
Perf 10Y	-99.35%
Recom	1.00
Target Price	25.71
Prev Close	2.50
Price	2.44
Change %	-2.40%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-04-26	Initiated	JP Morgan	Overweight	$27
Jan-07-26	Initiated	Piper Sandler	Overweight	$24
Apr-16-25	Initiated	Scotiabank	Sector Outperform	$12
Mar-14-25	Initiated	Cantor Fitzgerald	Overweight
Jul-10-23	Resumed	Guggenheim	Buy	$22
Jun-04-21	Initiated	H.C. Wainwright	Buy	$40
Feb-17-21	Initiated	Oppenheimer	Outperform	$43
Oct-19-20	Initiated	Cowen	Outperform	$50
Jul-29-20	Initiated	Guggenheim	Buy	$50

Oct-15-26 08:00AM	Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support (GlobeNewswire)
Sep-08-26 04:05PM	Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Aug-11-26 08:11AM	Protara Therapeutics: Q2 Earnings Snapshot (Associated Press)
08:00AM	Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update (GlobeNewswire)
May-20-26 08:00AM	Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA (GlobeNewswire) +9.68%
08:00AM	Loading…
May-18-26 08:00AM	Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026 (GlobeNewswire) -9.80%
May-15-26 07:00AM	Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naive Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC (GlobeNewswire)
May-13-26 08:06AM	Protara Therapeutics: Q1 Earnings Snapshot (Associated Press)
08:00AM	Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-27-26 04:05PM	Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients at the American Urological Association Annual Meeting (GlobeNewswire)
Mar-10-26 08:10AM	Protara Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Mar-01-26 08:36PM	Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf (MarketBeat)
Feb-25-26 03:12AM	Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GU (MarketBeat) +8.96%
Feb-24-26 07:41AM	Protara's Experimental Bladder Cancer Drug Shows Encouraging Results (Benzinga) -26.38%
05:05PM	Loading…
Feb-23-26 05:05PM	TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (GlobeNewswire) +8.63%
Feb-19-26 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.20%
Feb-02-26 04:05PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-22-26 08:00AM	Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium (GlobeNewswire)
Jan-12-26 07:00AM	Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones (GlobeNewswire) -8.87%
Jan-07-26 08:00AM	Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +11.13%
08:00AM	Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support (GlobeNewswire)
Jan-05-26 08:00AM	Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Dec-08-25 04:05PM	Protara Announces Closing of $75 Million Public Offering (GlobeNewswire)
Dec-04-25 10:03PM	Protara Announces Pricing of $75 Million Public Offering (GlobeNewswire) -18.78%
04:15PM	Protara Announces Proposed Public Offering (GlobeNewswire)
Dec-03-25 08:00AM	Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients (GlobeNewswire) +9.32%
Dec-01-25 04:15PM	Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients on Wednesday, December 3, 2025 (GlobeNewswire) -8.67% -7.72%
Nov-19-25 08:00AM	Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Nov-18-25 04:30PM	Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025 (GlobeNewswire) +21.18%
08:00AM	Loading…
Nov-17-25 08:00AM	Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-10-25 08:06AM	Protara Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) +5.59%
08:00AM	Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-25 04:05PM	Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace (GlobeNewswire) -9.28%
Oct-01-25 04:03PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-21-25 06:15AM	Analysts Predict Up to 840% Jump for These 2 Strong Buy Penny Stocks (TipRanks)
Sep-02-25 04:05PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-27-25 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-11-25 06:14PM	Protara Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-25 04:08PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-25 04:12PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.59%
Jun-30-25 08:00AM	Protara Therapeutics Announces Addition to the Russell 3000 Index (GlobeNewswire) +5.21%
Jun-02-25 04:04PM	Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer (GlobeNewswire) +8.55%
May-13-25 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-08-25 08:00AM	Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-01-25 04:09PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-26-25 10:00AM	Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC (GlobeNewswire)
Apr-23-25 08:00AM	Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025 (GlobeNewswire) +6.60%
Apr-15-25 04:13PM	Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer (GlobeNewswire)
Apr-10-25 04:05PM	Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting (GlobeNewswire) -6.25%
Apr-09-25 12:00PM	Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade (Zacks) +6.67%
Mar-28-25 05:10PM	Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results (Seeking Alpha) -6.99%
Mar-19-25 08:00AM	Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support (GlobeNewswire) +8.78%
Mar-05-25 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire) +8.04%
Feb-26-25 08:00AM	Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-05-25 08:00AM	Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-13-25 08:00AM	Protara Highlights Recent Updates and Anticipated 2025 Milestones (GlobeNewswire)
Jan-08-25 08:00AM	Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-24 04:05PM	Protara Announces Closing of $100 Million Public Offering (GlobeNewswire)
Dec-09-24 11:35PM	Protara Announces Pricing of $100 Million Public Offering (GlobeNewswire) +12.86% -6.30%
04:01PM	Protara Announces Proposed Public Offering (GlobeNewswire)
Dec-05-24 07:00AM	Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC (GlobeNewswire) +70.06%
Dec-03-24 08:00AM	Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024 (GlobeNewswire) +11.46%
Nov-15-24 05:52PM	Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology (GlobeNewswire) -6.48%
Nov-12-24 08:00AM	Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-06-24 08:00AM	Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference (GlobeNewswire) -6.13%
Oct-21-24 08:00AM	Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support (GlobeNewswire) +5.24%
Sep-09-24 08:05AM	Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support (GlobeNewswire)
Sep-03-24 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-06-24 08:00AM	Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Jun-24-24 05:06PM	Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.83%
May-21-24 08:00AM	Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire)
May-02-24 12:54PM	TARA Stock Earnings: Protara Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-12-24 09:55AM	Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Apr-05-24 08:04AM	Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing (GlobeNewswire) -9.70%
08:02AM	Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC (GlobeNewswire)
Mar-13-24 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-24 08:00AM	Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) -7.45%
Jan-31-24 07:30AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-30-23 08:30AM	Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-03-23 09:43AM	Protara Therapeutics Inc (TARA) Announces Q3 2023 Financial Results (GuruFocus.com) +11.57%
08:00AM	Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Oct-23-23 08:00AM	Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Sep-20-23 08:30AM	Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ (GlobeNewswire)
Sep-05-23 07:30AM	Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 08:00AM	Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-15-23 08:00AM	Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ (GlobeNewswire)
May-04-23 08:00AM	Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-02-23 08:00AM	Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Apr-28-23 08:00AM	Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development (GlobeNewswire)
Mar-08-23 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-01-23 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +10.76%
Feb-02-23 08:00AM	Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day (GlobeNewswire)
Jan-30-23 08:00AM	Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer (GlobeNewswire)
Dec-01-22 08:00AM	Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-03-22 08:00AM	Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shefferman Jesse	CEO and President	Jun 29 '26	Option Exercise	1.91	215,687	411,962	937,519	Jul 01 04:10 PM
Shefferman Jesse	CEO and President	Jun 29 '26	Sale	4.09	215,687	882,160	721,832	Jul 01 04:10 PM
JESSE SHEFFERMAN	Officer	Jun 29 '26	Proposed Sale	4.09	215,687	882,009		Jun 29 04:52 PM
Baker Brothers Life Sciences,	Former Affiliate	Apr 23 '26	Proposed Sale	5.35	300,176	1,605,942		Apr 23 08:42 PM
667, L.P.	Former Affiliate	Apr 23 '26	Proposed Sale	5.35	24,802	132,691		Apr 23 08:41 PM
Zummo Jacqueline	Chief R&D Officer	Apr 08 '26	Sale	5.40	1,134	6,124	94,827	Apr 09 05:25 PM
Zummo Jacqueline	Chief R&D Officer	Apr 01 '26	Sale	5.26	22,598	118,865	95,961	Apr 02 04:05 PM
Zummo Jacqueline	Officer	Apr 01 '26	Proposed Sale	5.26	23,732	124,826		Apr 01 10:32 AM
667, L.P.	Former Affiliate	Mar 06 '26	Proposed Sale	5.85	38,277	223,920		Mar 06 05:51 PM
Baker Brothers Life Sciences,	Former Affiliate	Mar 06 '26	Proposed Sale	5.85	461,723	2,701,080		Mar 06 05:50 PM
667, L.P.	Former Affiliate	Mar 04 '26	Proposed Sale	6.26	35,173	220,151		Mar 04 08:37 PM
Baker Brothers Life Sciences,	Former Affiliate	Mar 04 '26	Proposed Sale	6.26	424,125	2,654,641		Mar 04 08:35 PM
667, L.P.	Former Affiliate	Feb 25 '26	Proposed Sale	5.81	78,716	457,046		Feb 25 07:58 PM
Baker Brothers Life Sciences,	Former Affiliate	Feb 25 '26	Proposed Sale	5.81	947,479	5,501,316		Feb 25 07:57 PM
667, L.P.	Former Affiliate	Feb 24 '26	Proposed Sale	6.04	26,755	161,584		Feb 24 09:13 PM
Baker Brothers Life Sciences,	Former Affiliate	Feb 24 '26	Proposed Sale	6.04	322,039	1,944,922		Feb 24 09:11 PM

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Co-founderMr. Jesse Shefferman

M.P.H.Dr. Jacqueline Zummo M.B.A.

Chief Financial OfficerMr. Patrick Fabbio M.B.A.

VPMs. Hannah Fry

Senior Vice President of Investor Relations & Corporate AffairsMs. Justine O'Malley

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TARA

Protara Therapeutics Inc

Upgrade your Finviz experience